Pracinostat/Vidaza Combination Shows Response in Phase II Leukemia Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Updated results from a phase II study of elderly patients with newly diagnosed acute myeloid leukemia showed that to date, in 50 patients treated with Pracinostat in combination with azacitidine (Vidaza), 27 patients achieved complete response, plus complete response with incomplete blood count recovery plus morphologic leukemia-free state, including 16 patients who achieved a CR.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login